PF-Atlas › Clinical Trials › NCT00768300
Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
Ambrisentan · Phase 3
Registry ID
NCT00768300
Phase
Phase 3
Status
Terminated
Drug / intervention
Ambrisentan
Sponsor
Gilead Sciences
Start
2008-12
Enrollment
494
Locations
185
About this trial
The ARTEMIS-IPF study was conducted to determine if ambrisentan was effective in delaying disease progression and death in participants with idiopathic pulmonary fibrosis (IPF), to evaluate its safety, and to evaluate its effect on development of pulmonary hypertension, quality of life, and dyspnea (shortness of breath) symptoms in this participant population. Participants were randomized in a 2:1 ratio to receive ambrisentan or placebo, respectively. Participation in the study was to be up to 4 years, depending on how long it would take to enroll participants and observe study events. After randomization, visits to the clinic took place every 3 months, and laboratory procedures were performed every month.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00768300 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.